CNS Drugs

, Volume 5, Issue 4, pp 278–292 | Cite as

Antidepressant Withdrawal Syndrome

Recognition, Prevention and Management
  • Michel Lejoyeux
  • Jean Adès
  • Sabelle Mourad
  • Jacquelyn Solomon
  • Steven Dilsaver
Drug Therapy



Withdrawal from tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs) and selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) can produce somatic and psychological distress. Influenza-like syndromes, gastrointestinal adverse effects, arrhythmias, anxiety, sleep disturbances, movement disorders, mania or hypomania, panic attacks and delirium may follow antidepressant withdrawal. At present, the aetiology of withdrawal symptoms is not fully known.

Withdrawal phenomena are usually prevented by gradually reducing the total daily dosage of the drug in question rather than abruptly discontinuing it. Antimuscarinic agents can be prescribed in order to alleviate the symptoms produced by the withdrawal of TCAs and MAOIs. To date, no drugs have been shown to be useful in the treatment of SSRI-associated withdrawal symptoms. The withdrawal syndrome associated with MAOIs may constitute a medical emergency.


Paroxetine Imipramine Withdrawal Symptom Clomipramine Withdrawal Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mann AM, MacPherson A. Clinical experience with imipramine (G22355) in the treatment of depression. Can Psychiatr Assoc J 1959; 4: 38–47PubMedGoogle Scholar
  2. 2.
    Andersen H, Kristiansen ES. Tofranil treatment of endogenous depressions. Acta Psychiatr Scand 1959; 34: 387–97PubMedCrossRefGoogle Scholar
  3. 3.
    Kramer JC, Klein DF, Fink M. Withdrawal symptoms following discontinuation of imipramine therapy. Am J Psychiatry 1961; 118: 549–50PubMedGoogle Scholar
  4. 4.
    Law W, Petti TA, Kazdin A. Withdrawal symptoms after graduated cessation of imipramine in children. Am J Psychiatry 1981; 118: 647–50Google Scholar
  5. 5.
    Bialos D, Giller E, Jatlow P, et al. Recurrence of depression after discontinuation of amitriptyline. Am J Psychiatry 1982; 139: 325–9PubMedGoogle Scholar
  6. 6.
    Tyrer P. Clinical effects of abrupt withdrawal from tricyclic antidepressants and monoamine oxidase inhibitors after longterm treatment. J Affect Disord 1984; 6: 1–7PubMedCrossRefGoogle Scholar
  7. 7.
    Geller B, Cooper TB, Carr LG. Prospective study of scheduled withdrawal from nortriptyline in children and adolescents. J Clin Psychopharmacol 1987; 7: 252–4PubMedGoogle Scholar
  8. 8.
    Diamond BI, Borison RL, Katz R, et al. Rebound reactions due to clomipramine. Psychopharmacol Bull 1989; 25 (2): 209–12PubMedGoogle Scholar
  9. 9.
    Otani K, Sasa H, Kaneko S, et al. Lack of withdrawal symptoms after discontinuation of mianserin. Lancet 1991; 337: 673–4PubMedCrossRefGoogle Scholar
  10. 10.
    Ceccherini-Nelli A, Bardellini L, Guazzalli M, et al. Antidepressant withdrawal phenomena: prospective findings [letter). Am J Psychiatry 1993; 150 (1): 165PubMedGoogle Scholar
  11. 11.
    Mallya G, White K, Gunderson C. Is there a serotoninergic withdrawal syndrome? Biol Psychiatry 1993; 33: 851–2PubMedCrossRefGoogle Scholar
  12. 12.
    Barr Le, Goodman WK, Price LH. Physical symptoms associated with paroxetine discontinuation [letter]. Am J Psychiatry 1994; 151 (21): 289PubMedGoogle Scholar
  13. 13.
    Keuthen NJ, Cyr P, Ricciardi JA, et al. Medication withdrawal symptoms in obsessivecompulsive disorder patients treated with paroxetine. J Clin Psychopharmacol 1994; 14 (31): 206–7PubMedCrossRefGoogle Scholar
  14. 14.
    Einbinder E. Fluoxetine withdrawailleneri? Am J Psychiatry 1995; 152 (81): 1235PubMedGoogle Scholar
  15. 15.
    Baer L, Ricciardi J, Keuthen N, et al. Discontinuing obsessivecompulsive disorder medication with behavior therapy Ilet terl. Am J Psychiatry 1995; 151 (121: 1842Google Scholar
  16. 16.
    Lejoyeux M, Rouillon F, Ades J, et al. A retrospective study of the effects of withdrawing antidepressants [abstract]. Neuropsychopharmacology 1994 May; 10 (35Pt2): 47SGoogle Scholar
  17. 17.
    MacMahon TC. A clinical overview of syndromes following withdrawal of antidepressants. Hosp Community Psychiatry 1986 Sept; 37 (9): 883–4Google Scholar
  18. 18.
    Dilsaver Se, Greden JE, Snider RM. Antidepressant withdrawal syndromes: phenomenology and physiopathology. Int Clin Psychopharmacol 1987; 2: 1–19PubMedCrossRefGoogle Scholar
  19. 19.
    Dilsaver Se. Withdrawal phenomena associated with antidepressant and antipsychotic agents. Drug Saf 1994; 10 (21: 103–14PubMedCrossRefGoogle Scholar
  20. 20.
    Boisvert D, Chouinard G. Rebound cardiac arrhythmia after withdrawal from imipramine: a case repon. Am J Psychiatry 1981; 138: 985–6PubMedGoogle Scholar
  21. 21.
    Dilsaver Se, Feinberg M, Greden JE. Antidepressant withdrawal symptoms treated with anticholinergic agents. Am J Psychiatry 1983; 140 (2): 249–51PubMedGoogle Scholar
  22. 22.
    Gualtieri CT, Staye J. Withdrawal symptoms after abrupt cessation of amitriptyline in an eight-year-old boy. Am J Psychiatry 1979; 136: 457–8PubMedGoogle Scholar
  23. 23.
    Shatan C. Withdrawal after abrupt termination of imipramine. Can Psychiatr Assoc J 1966 Suppl.: 150–8Google Scholar
  24. 24.
    Webster PAC. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet 1973; 2: 318–9PubMedCrossRefGoogle Scholar
  25. 25.
    Gawin FH, Markoff RA. Panic anxiety after abrupt discontinuation of amitriptyline. Am J Psychiatry 1981; 138: 117–8PubMedGoogle Scholar
  26. 26.
    Davison P, Wardrope J. Acute amitriptyline withdrawal and hyponatraemia. Drug Saf 1993; 8 (1): 78–80PubMedCrossRefGoogle Scholar
  27. 27.
    Brown GM, Stancer He, Moldofsky H, et al. Withdrawal from long-term high-dose desipramine therapy; clinical and biological changes. Arch Gen Psychiatry 1978; 35: 1261–4PubMedCrossRefGoogle Scholar
  28. 28.
    Dilsaver Se, Kronfol Z, Greden JF, et al. Antidepressant withdrawal syndromes: evidences supponing the cholinergic overdrive hypothesis. J Clin Psychopharmacol 1983; 3: 157–64PubMedGoogle Scholar
  29. 29.
    Sathananthan GL, Gershon S. Imipramine withdrawal: an akathisia-Iike syndrome. Am J Psychiatry 1973; 130: 1286–7PubMedGoogle Scholar
  30. 30.
    Weller RA, McKnelly Jr wv. Case repon of withdrawal dyskinesia associated with amoxapine. Am J Psychiatry 1983; 140 (111: 1515–6PubMedGoogle Scholar
  31. 31.
    Lejoyeux M, Rodiere-Rein C, Ades J. Syndrome de seHage des antiJepreeurs, Desiptiun de cin4 cas. Encephalc 1992; 18: 251–5Google Scholar
  32. 32.
    Dilsaver Sc, Greden JF. Antidepressant withdrawal-induced activation I hypomania and mania): mechanism and theoretical significance. Brain Res Rev 1984; 7: 29–48CrossRefGoogle Scholar
  33. 33.
    Ghadirian AM. Paradoxical mood response following antidepressant withdrawal. Bioi Psychiatry 1986; 21: 1298–300CrossRefGoogle Scholar
  34. 34.
    Hanman PM. Mania or hypomania after withdrawal from antidepressants. J Fam Pract 1990; 30: 4712Google Scholar
  35. 35.
    Mirin SM, Schatzberg AF, Creasey DE. Hypomania and mania after withdrawal of tricyclic antidepressants. Am J Psychiatr 1981; 138: 87–9PubMedGoogle Scholar
  36. 36.
    Nelson Je, Schonenfield RS, Condrad ED. Hypomania after desipramine withdrawal. Am J Psychiatry 1983; 140: 624–5PubMedGoogle Scholar
  37. 37.
    Van Scheyen JD, van Kammen DP. Clomipramine-induced mania in unipolar depression. Arch Gen Psychiatry 1979; 560-5Google Scholar
  38. 38.
    Halle MH, Del Medico VJ, Dilsaver Sc. Symptoms of major depression: acute effect of withdrawing antidepressants. Acta Psychiatr Scand 1991; 83: 238–9PubMedCrossRefGoogle Scholar
  39. 39.
    Van Sweden B. Rebound antidepressant cardiac arrhythmia. Bioi Psychiatry 1988; 24: 363–4CrossRefGoogle Scholar
  40. 40.
    Liskin B, Roose S, Walsh T. Acute psychosis following phenelzine discontinuation. J Clin Psychopharmacol 1984; 5: 46–7Google Scholar
  41. 41.
    Roth SD. More on psychosis following phenelzine discontinuation. J Clin Psychopharmacology 1985; 5: 360–1CrossRefGoogle Scholar
  42. 42.
    Halle MT, Dilsaver Sc. Tranylcypromine withdrawal phenomena. J Psychiatry Neurosci 1993; 18 (11: 49–50PubMedGoogle Scholar
  43. 43.
    Frankel DA, Raskin DE. Psychosis following phenelzine discontinuation [letter]. J Clin Psychopharmacol 1985; 5: 360Google Scholar
  44. 44.
    Le Gassicke J, Ashcroft GW, Eccleston D, et al. The clinical state, sleep and amine metabolism uf a tranylcypromine spamatel addict. Br J Psychiatry 1965; 3: 357–64CrossRefGoogle Scholar
  45. 45.
    Dilsaver Sc, Greden JF. Antidepressant withdrawal phenomena. Bioi Psychiatry 1984; 19: 237–56Google Scholar
  46. 46.
    Pagliaro LA, Pagliaro AM. Abuse potential of antidepressants: does it exist? CNS Drugs 1995; 4: 247–52CrossRefGoogle Scholar
  47. 47.
    Lejoyeux M. Dependance aux antidepresseurs: authentique addiction? L’Encephale 1995; 21 (No Special 1: 63–5PubMedGoogle Scholar
  48. 48.
    Vartzopulos D, Krull E. Dependence on monoamine oxidase inhibitors in high dose. Br J Psychiatry 1991; 158: 856–7CrossRefGoogle Scholar
  49. 49.
    Debanista C, Schatzberg AE. Physical symptoms associated with paroxetine withdrawal. Am J Psychiatry 1995; 152 (8): 12356Google Scholar
  50. 50.
    Fava GA, Grandi S. Withdrawal syndromes after paroxetine and sertraline discontinuation. J Clin Psychopharmacol 1995; 15: 374–5PubMedCrossRefGoogle Scholar
  51. 51.
    Pyke RE. Paroxetine withdrawal syndrome. Am J Psychiatry 1995; 152 (1): 149–50PubMedGoogle Scholar
  52. 52.
    D’Arcy PE. Dystonia and withdrawal symptoms with paroxetine [letter]. Int Pharm J 1993; 7: 140Google Scholar
  53. 53.
    Bioch M, Stager SV, Braun AR, et al. Severe psychiatric symptoms associated with paroxetine withdrawal [letter]. Lancet 1995 Jul; 346: 57Google Scholar
  54. 54.
    Frost L, Lal S. Shock-like sensations after discontinuation of selective reuptake inhibitors IIenerl. Am J Psychiatry 1995; 152 (5): 810PubMedGoogle Scholar
  55. 55.
    Stoukides JA, Stoukides CA. Extrapyramidal symptoms upon discontinuation of fluoxetine Ileneri. Am J Psychiatry 1991; 148 (9): 1263PubMedGoogle Scholar
  56. 56.
    Lipinski Jr JE, Mallya G, Zimmerman P, et al. Fluoxetineinduced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989; 50: 339–42PubMedGoogle Scholar
  57. 57.
    Lejoyeux M, Ades J, Rouillon F. Serutonin syndrome: incidence, symptoms and outcome. CNS Drugs 1994; 2 (2): 132–43CrossRefGoogle Scholar
  58. 58.
    Kasantikul D. Reversible delirium after discontinuation of fluoxetine. J Med Assoc Thailand 1995; 78: 53–4Google Scholar
  59. 59.
    Otani K, Tanaka O, Kaneko S, et al. Mechanisms of the development of trazodone withdrawal symptoms. Int Clin Psychopharmacol 1994; 9: 131–3PubMedCrossRefGoogle Scholar
  60. 60.
    Petersen RC, Richelson E. Anticholinergic activity of imipramine and some analogues at muscarinic receptors of culture mouse neuroblastoma cells. Psychopharmacology 1982; 76: 26–8PubMedCrossRefGoogle Scholar
  61. 61.
    Snyder SH, Yarnamura HI. Antidepressants and muscarinic acetylcholine receptor. Arch Gen Psychiatry 1977; 34: 236–9PubMedCrossRefGoogle Scholar
  62. 62.
    Tollefson GO, Senogles SE, Frey WH, et al. A comparison of peripheral and central human muscarinic cholinergic receptor affinities for psychotropic drugs. Biol Psychiatry 1982; 17: 555–67PubMedGoogle Scholar
  63. 63.
    Rouillon F, Lejoyeux M, Filteau MJ. Unwanted effects of longtenn treatment. In: Montgomery S, Rouillon F, editors. Longtenn treatment of depression. Vol. 3. Chichester: John Wiley and Sons. 1992: 81–111Google Scholar
  64. 64.
    Dilsaver Sc. Antimuscarinic agents as substances of abuse: a review. J Clin Psychophannacol 1988; 8: 14–22Google Scholar
  65. 65.
    Dilsaver Sc. Cholinergic mechanisms in affective disorders. Further directions for investigation. Acta Psychiatr Scand 1986; 74: 312–34PubMedCrossRefGoogle Scholar
  66. 66.
    Dilsaver Sc. Cholinergic mechanisms in depression. Brain Res Rev 1986; 11: 285–316CrossRefGoogle Scholar
  67. 67.
    Dilsaver SC. Phannacologic induction of cholinergic system up-regUlation and supersensitivity in affective disorders research. J Clin Psychophannacol 1986; 7: 56–72Google Scholar
  68. 68.
    Charney OS, Heninger GR, Sternberg DE, et al. Abrupt discontinuation of tricyclic antidepressant drugs: evidence for noradrenergic hyperactivity. Br J Psychiatry 1982; 141: 377–86PubMedCrossRefGoogle Scholar
  69. 69.
    Charney OS, Menkes DB, Heninger GR. Receptor sensitivity and the mechanism of action of antidepressant treatment: implications for the etiology and theory of depression. Arch Gen Psychiatry 1981; 38: 1160–80PubMedCrossRefGoogle Scholar
  70. 70.
    Walsh BT, Stewan JW, Wright L, et al. Treatment of bulimia with monoamine oxidase inhibitors. Am J Psychiatry 1982; 139: 1629–30PubMedGoogle Scholar
  71. 71.
    Dilsaver SC. The pathophysiologies of substance abuse and affective disorders: an integrative model? J Clin Psychophannacol 1987; 7: 1–10CrossRefGoogle Scholar
  72. 72.
    Cohen RM, Campbell IC, Dauphin M, et al. Changes in alpha and beta receptor densities in rat brain as a result of treatment with monoamine oxidase inhibitor antidepressants. Neurophannacology 1982; 21: 293–8CrossRefGoogle Scholar
  73. 73.
    Chiodo LA, Antelman SM. Repeated tricyclics induce progressive dopamine autoreceptor subsensitivity independent of daily drug treatment. Nature 1980; 287: 451–4PubMedCrossRefGoogle Scholar
  74. 74.
    Creese I, Sibley DR. Receptor adaptations to centrally acting drugs. Annu Rev Phannacol Toxicol 1981; 21: 317–91Google Scholar
  75. 75.
    Kupfer OJ, Frank E. The minimum length of treatment for recovery. In: Montgomery S, Rouillon F, editors. Long-term treatment of depression. New York: John Wiley. 1992: 33–52Google Scholar
  76. 76.
    Dilsaver SC. Antidepressant withdrawal syndromes: phenomenology and pathophysiology. Acta Psychiatr Scand 1989; 79: 113–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Michel Lejoyeux
    • 1
  • Jean Adès
    • 2
  • Sabelle Mourad
    • 2
  • Jacquelyn Solomon
    • 1
  • Steven Dilsaver
    • 3
  1. 1.Department of PsychiatryBichat-Claude Bernard HospitalParisFrance
  2. 2.Department of PsychiatryLouis Mourier HospitalColombesFrance
  3. 3.Department of Psychiatry and Behavioural Sciences, Harris County Psychiatric CenterThe University of Texas, Health Science Center at HoustonHoustonUSA

Personalised recommendations